CoChat
Sign Up
Cited by 366Virus-based gene therapy researchHemophilia Treatment and ResearchRNA Interference and Gene Delivery

The DOI matches its Crossref record; 16 of the 18 references it cites were found in a registry or an index.

Several Log Increase in Therapeutic Transgene Delivery by Distinct Adeno-Associated Viral Serotype Vectors

Open access
Chao, Hengjun, Liu, Yuanbo, Rabinowitz, Joseph, Li, Chengwen, Samulski, Richard Jude, Walsh, Christopher E.·2000·Molecular Therapy
DOI 10.1006/mthe.2000.0219
Open this paper in CoChat — free accountOpen PDF

Abstract

We previously demonstrated that rAAV vectors carrying human and canine factor IX (FIX) cDNA can infect, stably persist, and secrete functional human and canine FIX following direct intramuscular injection. In an attempt to improve FIX protein secretion for eventual therapeutic use, we set out to determine if alteration of the AAV capsid would affect skeletal muscle transduction and factor IX secretion. Two reasons to pursue this question were (1) the persistence of high-titer neutralizing antibody (NAB) to AAV2 and (2) our previous study that supported a restricted tropism of muscle fiber types to AAV2 transduction. Using an identical CMV/canine factor IX (cFIX) expression cassette, we cross-packaged this genome into virions generated from each of the five AAV serotypes. In a dose-response assay, equivalent amounts of rAAV/cFIX serotypes were tested in vitro and in vivo. In tissue culture cells, FIX antigen levels secreted into the supernatant varied depending on the AAV serotype used; type 2 transduced maximally, with serotypes 3, 1, 5, and 4, respectively, expressing lower levels. However, when the same viruses were tested in vivo using immunodeficient NOD/SCID animals, we obtained surprisingly different results. While the time to onset of detectable serum levels appeared the same for all serotypes, types 1, 3, and 5 produced 100- to 1000-fold more cFIX than type 2. In fact, 12 weeks after transduction, type 1 continued to express levels of cFIX on average at 80 microg/ml followed by type 5 (6.52 microg/ml), type 3 (3.27 microg/ml), type 4 (258 ng/ml), and finally type 2 (90 ng/ml). Coagulant activity of cFIX as measured by aPTT supported the circulating levels measured by ELISA demonstrating the secreted protein was functional, and RT-PCR of injected tissue correlated with the serotype-specific transduction data. In summary, we found significant differences in cFIX expression upon introducing various rAAV serotypes into mouse muscle. These data have direct bearing on the design of AAV gene therapy clinical trials for hemophilia and should also extend to most therapeutic transgenes.

Overview

Integrity signals

Registry

Crossref · 10.1006/mthe.2000.0219

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 18 references

2 of the 18 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

See all 366

Related

Metadata

Authors
Chao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R. J., & Walsh, C. E.
Affiliations
University of North Carolina at Chapel Hill (US)
Corresponding author
Walsh, Christopher E.
ORCID
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2000-12
Volume
2
Issue
6
Pages
619-623
ISSN
1525-0016 (ISSN-L)
DOI
10.1006/mthe.2000.0219
OpenAlex
W2050245606
Cited by
366
References
18
Citations by year
2026: 5 · 2025: 1 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 6 · 2020: 1 · 2019: 6 · 2018: 4 · 2017: 6 · 2016: 5 · 2015: 13 · 2014: 12 · 2013: 8 · 2012: 10
FWCI
16.72
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Therapy (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01dk054419-04, 5r01hl048347-09)
  • National Heart, Lung, and Blood Institute (HL 48347)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK54419)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
adeno-associated virus serotypes, skeletal muscle transduction, neutralizing antibodies, intramuscular injection, coagulant activity
MeSH terms
Dependovirus, Animals, Dogs, Factor IX, Genetic Vectors, Transduction, Genetic, Mice, SCID, Mice, Inbred NOD, Transgenes, Reverse Transcriptase Polymerase Chain Reaction, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review